Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 1/20 | 0.86 |
| ▸ | PDE4A | P27815 | 1/20 | 0.86 |
| ▸ | KDR | P35968 | 1/20 | 0.86 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28864397 | 1.00 | HIF1A (0.86) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL11442745 | 1.00 | — | — | |
| Piperazine SCHEMBL27901557 | 0.94 | — | — | |
| SCHEMBL576335 | 0.93 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL5033222 | 0.93 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL577429 | 0.93 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Aziridine SCHEMBL7968853 | 0.93 | — | — | |
| Piperazine SCHEMBL734764 | 0.93 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL22003 | 0.93 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL8199316 | 0.93 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3176155-B1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | CATEXEL LTD (GB) | 2019-09-25 | — | — | EP | disclosed |
| EP-3176155-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | Catexel Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-2590952-B1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE THEREOF | CATEXEL LTD (GB) | 2017-01-18 | — | — | EP | disclosed |
| US-8907082-B2 | 1,2-bis-(4,7-dimethyl-1,4,7-triazacyclonon-1-yl)-ethane and intermediate for the synthesis of same | CATEXEL LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130261297-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | CATEXEL LIMITED (GB) | 2013-10-03 | — | — | US | disclosed |
| EP-2590952-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE THEREOF | Catexel Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012003712-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE THEREOF | UNILEVER PLC (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261297-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | DHPS, CYP51A1, BID | HIF1A 1667/4885MAPT 4020/4885PDE4A 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.